Three Zhangjiang Companies Secure New Funding Rounds and Advance Toward IPO

Recently,OYMotionOYMotion Announces Completion of Nearly RMB100 Million Series B++ Financing Round. This Round was Jointly Invested by Infiniti Capital, Zhejiang Development Asset Management Co., Ltd. (under Zhejiang Provincial State Capital Operation Co., Ltd.), and Vantage Capital. LK Capital Served as the Long-term Financial Advisor. This is a New Round of Financing Quickly Closed within 3 Months after OYMotion Completed its Series B+ Financing at the End of 2024.

In 2015, OYMotion was founded in Zhangjiang Science City. As one of the few innovative companies in China that simultaneously masters two core underlying technologies—brain-computer interface and robotics—the company has consistently focused on the cross-integration of brain science and robotics technology. It has successfully built a self-developed platform that integrates "neural interface-robot-AI algorithm" into a trinity. After nearly a decade of technological accumulation, OYMotion has developed multiple innovative products that combine technical leadership with commercial viability, earning widespread recognition in the global market for their performance and cost-effectiveness.

Zhuhai Greater Bay Area · Core Production and Manufacturing Base

This round of financing will inject strong momentum into OYMotion, assisting the company in achieving leapfrog development in multiple key areas. The funds will be primarily used to accelerate continuous R&D breakthroughs in the dexterous hand technology field, promote the launch process of the next-generation dexterous hand products, and expedite the market entry of finger joint exoskeleton robots. Meanwhile, a world-leading standardized production system will be established, optimizing production processes to achieve a 100% increase in annual production capacity. Additionally, OYMotion will further advance its global market layout, providing higher quality and more efficient solutions to customers worldwide.

OYMotion ROH-A001 Dexterous Hand

OYMotion's Dexterous Hand Application in the Field of Embodied Robotics

May 9,Sirius TherapeuticsSirius Therapeutics (SHANGHAI) Co., Ltd. Announces Nearly 50 Million USD in Series B2 Financing to Accelerate Clinical Development of Novel siRNA Therapies for Cardiometabolic Diseases and Continue Innovation in Next-Generation RNA Delivery Technology. This round of financing was led by a globally renowned industry investment institution, with participation from BioTrack Capital and existing investors Orbimed, Hongyuan Capital, and H&Q Healthcare.

Sirius Therapeutics was founded in 2021 and is dedicated to developing groundbreaking siRNA therapies for the prevention and treatment of chronic diseases. The company was incubated by an international management team and globally renowned healthcare investment institutions. With a strategic international outlook, Sirius Therapeutics leverages talent and resources from both the U.S. and China in the field of small nucleic acid therapies. It has established a layout with the U.S. as the center for innovative discovery and China as the global translational medicine hub. Utilizing its core technology platform for small nucleic acid drug development, the company has built a diverse pipeline with multiple products that have "first-in-class" or "best-in-class" potential.

The company has currently developed three clinical-stage projects and multiple preclinical product pipelines. Among them, SRSD107, the novel anticoagulant therapy with the fastest progress, represents a new generation of long-acting anticoagulants for the treatment and prevention of thromboembolic diseases, and its European Phase 2 clinical trial application has been submitted to the European Medicines Agency (EMA). SRSD216, a novel siRNA therapy targeting elevated lipoprotein(a), has received approvals from the U.S. FDA and China’s NMPA and is currently in Phase 1 clinical trials. Another siRNA therapy for hyperlipidemia, SRSD101, is also steadily advancing in clinical development in China.